Search Results
Optimizing Biosimilars for Safe and Effective Management of IMIDs
Utilization of Biosimilars: Achieving Value-Based Plan Management
Biosimilars for IBD: To Start, Switch, or Stay Away?
Interchangeability 101 - Biosimilars & Interchangeable Biologics
The Current Landscape of Biosimilars in IBD
Dr. Litton Discusses the Potential Advantage of Using Biosimilars in Oncology
2017 FDA Guidance on Biosimilars
Comment: Immunogenicity of biosimilars
BC expands use of biosimilars
The science of biosimilarity: Immunogenicity
The BPCIA and the Naming of Biosimilars
Comparison of Biologics to Biosimilars Versus Generics
